A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction
To me it appears ACEi is useful pari passu with Systolic LV Dysfunction. The patient following AMI with normal LV systolic function is least likely to gain, unless some other indication of ACEi therapy like hypertension is present.
To me it appears ACEi is useful pari passu with Systolic LV Dysfunction. The patient following AMI with normal LV systolic function is least likely to gain, unless some other indication of ACEi therapy like hypertension is present.